Clinical Trial Goal
To find out:
- The highest dose of selinexor and venetoclax that's safe to give
- If the combination of dexamethasone, selinexor and venetoclax is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have multiple myeloma that has relapsed or is refractory
- Have myeloma cells with a translocation of chromosomes 11 and 14. Your doctor can tell you this
- Have not been treated with a SINE compound like selinexor
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Dexamethasone is a drug that reduces inflammation.
Selinexor is a small molecule inhibitor that blocks XPO1 in certain cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Selinexor is a small molecule inhibitor that blocks XPO1 in certain cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Dexamethasone – A pill that you take by mouth 1 time each week
- Selinexor – A pill that you take by mouth 1 time each week
- Venetoclax – A pill that you take by mouth 1 time each day
You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat multiple myeloma that has relapsed or is refractory is new and unproven.
Locations
University of Miami, Lennar Foundation Medical CenterRECRUITING
Coral Gables, Florida
Contacts:
- Alanna Vossen, 305-243-7701, avossen@miami.edu
- Dickran Kazandjian, MD, 718-795-6027, dkazandjian@miami.edu
University of Miami, Sylvester Comprehensive Cancer CenterRECRUITING
Miami, Florida
Contacts:
- Alanna Vossen, 305-243-7701, avossen@miami.edu
- Dickran Kazandjian, MD, dkazandjian@miami.edu
University of Miami, Sylvester Comprehensive Cancer Center at Deerfield BeachRECRUITING
Deerfield Beach, Florida
Contacts:
- Alanna Vossen, 305-243-7701, avossen@miami.edu
- Dickran Kazandjian, MD, 718-795-6027, dkazandjian@miami.edu
Sponsors
collaborator: Karyopharm Therapeutics Inc, lead: University of Miami
